Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | GRM5 | P41594 | 5/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29479760 | 0.88 | S1PR5 (0.48) | S1PR5GRIN2BDHFRPPARAMEN1 | |
| SCHEMBL23012259 | 0.88 | S1PR5 (0.48) | S1PR5GRIN2BDHFRPPARAMEN1 | |
| SCHEMBL505215 | 0.85 | GRM5 (0.56) | S1PR5GRIN2BDHFRGRM5KCNH2 | |
| SCHEMBL29479674 | 0.84 | S1PR5 (0.47) | S1PR5GRIN2BDHFRPPARAKDR | |
| SCHEMBL20775591 | 0.84 | S1PR5 (0.50) | S1PR5S1PR1S1PR3 | |
| SCHEMBL505382 | 0.84 | PPARA (0.50) | S1PR5DHFRPPARAMEN1KMT2A | |
| SCHEMBL505282 | 0.84 | S1PR5 (0.48) | S1PR5GRIN2BDHFRMEN1KMT2A | |
| SCHEMBL505149 | 0.82 | GRM5 (0.49) | S1PR5DHFRPPARAMEN1KMT2A | |
| SCHEMBL17377166 | 0.82 | DHFR (0.49) | DHFRPPARAMEN1KMT2ANPSR1 | |
| SCHEMBL504611 | 0.81 | CYP2C9 (0.50) | S1PR5CYP2D6CYP2C9GRIN2BDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414340-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | S1PR5 476/4885CYP2D6 3481/4885CYP2C9 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.